Earnings calls

Ipca Labs. concall ledger

Every earnings call for IPCALAB — management tone, guidance, KPIs and promise tracking, quarter by quarter.

IPCALAB · 5 transcripts · Healthcare · latest Q3 FY26

Q3 FY26Published 16 Feb 2026Call held 16 Feb 2026

IPCALAB Q3 FY26 Earnings Call Transcript & Analysis

Consolidated Revenue₹2,393 cr+7% YoYConsolidated EBITDA Margin22.5%

Consolidated Revenue ₹2,393 cr (+6% YoY); Consolidated EBITDA Margin 22.5%. Consolidated business grew 6.5% to ₹2,393 crores in Q3 FY26.

Q2 FY26Published 13 Nov 2025Call held 13 Nov 2025

Standalone EBITDA Margin25.46%

Standalone EBITDA Margin 25.46%. Domestic formulation business grew ~8% in Q2 FY26, outpacing IPM growth of 7.8%.

Q1 FY26Published 12 Aug 2025Call held 12 Aug 2025

Standalone EBITDA Margin23.82%Standalone Net Profit₹262 cr+26% YoY

Standalone EBITDA Margin 23.82%; Standalone Net Profit ₹262 cr (+26% YoY). Standalone net profit up 26% to Rs. 262 crores.

Q4 FY25Published 30 May 2025Call held 30 May 2025

Consolidated EBITDA₹1,693 cr+31% YoYConsolidated EBITDA Margin18.94%+2% YoY

Consolidated EBITDA ₹1,693 cr (+31% YoY); Consolidated EBITDA Margin 18.94% (+2% YoY). Domestic business grew 12% for FY25, outpacing market growth.

Q3 FY25Published 13 Feb 2025Call held 13 Feb 2025

Standalone EBITDA Margin24.25%+6% YoY

Standalone EBITDA Margin 24.25% (+6% YoY). Standalone EBITDA margin expanded 573bps to 24.25% in Q3 FY25.